Drugs / EBV TCR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07162012 | Sep 2025 → Sep 2028 expected | diffuse large B-cell lymphoma, mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV TCR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07162012 ↗ |
| Modality | Cell therapy | “infused TCR-T cells” NCT07162012 ↗ |